|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer Statistics, 2021. CA Cancer J Clin. 71:7–33. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Åkesson Å, Adok C and Dahm-Kähler P:
Recurrence and survival in endometrioid endometrial cancer-a
population-based cohort study. Gynecol Oncol. 168:127–134. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Åkesson Å, Adok C and Dahm-Kähler P:
Increased survival in non-endometrioid endometrial cancer after
introducing lymphadenectomy and tailoring radiotherapy-A
population-based cohort study. Eur J Cancer. 169:54–63. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee SJ, Kang HJ, Kwak YK, Kim M and Kim J:
Non-endometrioid endometrial cancer: Analysis of recurrence pattern
and identification of prognostic and treatment factors affecting
recurrence and survival. Strahlenther Onkol. 199:828–837. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Feng J, Zhang Y, Huang C, Li L, Liu J,
Wang J, Guo H, Yao S, Cui Z, Chen G, et al: Prognostic evaluation
of lymph-vascular space invasion in patients with endometrioid and
non-endometrioid endometrial cancer: A multicenter study. Eur J
Surg Oncol. 50:1082612024. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stelloo E, Nout RA, Osse EM,
Jürgenliemk-Schulz IJ, Jobsen JJ, Lutgens LC, van der Steen-Banasik
EM, Nijman HW, Putter H, Bosse T, et al: Improved risk assessment
by integrating molecular and clinicopathological factors in
early-stage endometrial cancer-combined analysis of the PORTEC
cohorts. Clin Cancer Res. 22:4215–4224. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Karnezis AN, Leung S, Magrill J, McConechy
MK, Yang W, Chow C, Kobel M, Lee CH, Huntsman DG, Talhouk A, et al:
Evaluation of endometrial carcinoma prognostic immunohistochemistry
markers in the context of molecular classification. J Pathol Clin
Res. 3:279–293. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
León-Castillo A, de Boer SM, Powell ME,
Mileshkin LR, Mackay HJ, Leary A, Nijman HW, Singh N, Pollock PM,
Bessette P, et al: Molecular classification of the PORTEC-3 trial
for high-risk endometrial cancer: Impact on prognosis and benefit
from adjuvant therapy. J Clin Oncol. 38:3388–3397. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Uijterwaal MH, van Dijk D, Lok CAR, De
Kroon CD, Kasius JC, Zweemer R, Gerestein CG, Horeweg N, Bosse T,
van der Marel J, et al: Prognostic value of molecular
classification in stage IV endometrial cancer. Int J Gynecol
Cancer. 34:847–854. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vizza E, Bruno V, Cutillo G, Mancini E,
Sperduti I, Patrizi L, Certelli C, Zampa A, Giannini A and Corrado
G: Prognostic role of the removed vaginal cuff and its correlation
with L1CAM in low-risk endometrial adenocarcinoma. Cancers (Basel).
14:342021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Giannini A, D'Oria O, Corrado G, Bruno V,
Sperduti I, Bogani G, Laganà AS, Chiantera V, Caserta D and Vizza
E: The role of L1CAM as predictor of poor prognosis in stage I
endometrial cancer: A systematic review and meta-analysis. Arch
Gynecol Obstet. 309:789–799. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu QJ, Zhang TN, Chen HH, Yu XF, Lv JL,
Liu YY, Liu YS, Zheng G, Zhao JQ, Wei YF, et al: The sirtuin family
in health and disease. Signal Transduct Target Ther. 7:4022022.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yuan H and Marmorstein R: Structural basis
for sirtuin activity and inhibition. J Biol Chem. 287:42428–42435.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Michishita E, Park JY, Burneskis JM,
Barrett JC and Horikawa I: Evolutionarily conserved and
nonconserved cellular localizations and functions of human SIRT
proteins. Mol Biol Cell. 16:4623–4635. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Costa-Machado LF and Fernandez-Marcos PJ:
The sirtuin family in cancer. Cell Cycle. 18:2164–2196. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhao E, Hou J, Ke X, Abbas MN, Kausar S,
Zhang L and Cui H: The roles of sirtuin family proteins in cancer
progression. Cancers (Basel). 11:19492019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Saffar H, Nili F, Sarmadi S, Barazandeh E
and Saffar H: Evaluation of sirtuin1 overexpression by
immunohistochemistry in cervical intraepithelial lesions and
invasive squamous cell carcinoma. Appl Immunohistochem Mol Morphol.
31:128–131. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zeng Z, Huang Y, Li Y, Huang S, Wang J,
Tang Y and Jiang Y: Gene expression and prognosis of sirtuin family
members in ovarian cancer. Medicine (Baltimore). 99:e206852020.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Han O, Alci A, Yildirim HT, Gokkaya M,
Yalcin N, Kandemir S, Goksu M, Ureyen I and Toptas T: βcatenin
expression in endometrioid type endometrial cancer: Expression
patterns and impact on disease outcomes. Oncol Lett. 28:5802024.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Remmele W and Stegner HE: Recommendation
for uniform definition of an immunoreactive score (IRS) for
immunohistochemical estrogen receptor detection (ERICA) in breast
cancer tissue. Pathologe. 8:138–140. 1987.PubMed/NCBI
|
|
21
|
Lin L, Zheng X, Qiu C, Dongol S, Lv Q,
Jiang J, Kong B and Wang C: SIRT1 promotes endometrial tumor growth
by targeting SREBP1 and lipogenesis. Oncol Rep. 32:2831–2835. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Huang S, Li Y, Sheng G, Meng Q, Hu Q, Gao
X, Shang Z and Lv Q: Sirtuin 1 promotes autophagy and proliferation
of endometrial cancer cells by reducing acetylation level of LC3.
Cell Biol Int. 45:1050–1059. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bartosch C, Monteiro-Reis S, Almeida-Rios
D, Vieira R, Castro A, Moutinho M, Rodrigues M, Graça I, Lopes JM
and Jerónimo C: Assessing sirtuin expression in endometrial
carcinoma and non-neoplastic endometrium. Oncotarget. 7:1144–1154.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Asaka R, Miyamoto T, Yamada Y, Ando H,
Mvunta DH, Kobara H and Shiozawa T: Sirtuin 1 promotes the growth
and cisplatin resistance of endometrial carcinoma cells: A novel
therapeutic target. Lab Invest. 95:1363–1373. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Al-Maghrabi J and Al-Maghrabi H: SIRT1 is
overexpressed in endometrial adenocarcinoma: A tissue microarray
analysis. Eur J Gynaecol Oncol. 41:699–704. 2020. View Article : Google Scholar
|
|
26
|
Beyer S, Chen F, Meister S, Czogalla B,
Kolben TM, Hester A, Burges A, Trillsch F, Schmöckel E, Mayr D, et
al: Sirtuin1 expression and survival in endometrial and clear-cell
uterine cancer. Histochem Cell Biol. 154:189–195. 2020. View Article : Google Scholar : PubMed/NCBI
|
